21.58
                                            Schlusskurs vom Vortag:
              $21.27
            Offen:
              $21.27
            24-Stunden-Volumen:
                46,398
            Relative Volume:
              0.07
            Marktkapitalisierung:
                $969.42M
            Einnahmen:
              $681.75M
            Nettoeinkommen (Verlust:
              $70.47M
            KGV:
              14.88
            EPS:
                1.45
            Netto-Cashflow:
                $173.19M
            1W Leistung:
              -0.70%
            1M Leistung:
              -16.23%
            6M Leistung:
                -19.75%
            1J Leistung:
              +30.04%
            Pacira Biosciences Inc Stock (PCRX) Company Profile
Firmenname
                  
                      Pacira Biosciences Inc
                    
                Sektor
                  Telefon
                  
                      650-242-8052
                    
                Adresse
                  
                      2000 SIERRA POINT PARKWAY, BRISBANE, NJ
                    
                Vergleichen Sie PCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV | 
|---|---|---|---|---|---|---|
|   
                          
                                PCRX
                            
                             Pacira Biosciences Inc | 21.57 | 955.72M | 681.75M | 70.47M | 173.19M | 1.45 | 
|   
                          
                                ZTS
                            
                             Zoetis Inc | 142.96 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 | 
|   
                          
                                TAK
                            
                             Takeda Pharmaceutical Co Adr | 13.42 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 | 
|   
                          
                                HLN
                            
                             Haleon Plc Adr | 9.235 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 | 
|   
                          
                                TEVA
                            
                             Teva Pharmaceutical Industries Ltd Adr | 20.08 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 | 
|   
                          
                                UTHR
                            
                             United Therapeutics Corp | 447.05 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 | 
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung | 
|---|---|---|---|
| 2025-07-25 | Hochstufung | Truist | Hold → Buy | 
| 2025-01-30 | Hochstufung | Truist | Sell → Hold | 
| 2024-08-13 | Herabstufung | Truist | Buy → Sell | 
| 2024-08-12 | Herabstufung | JP Morgan | Overweight → Underweight | 
| 2024-08-12 | Herabstufung | Piper Sandler | Overweight → Neutral | 
| 2024-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform | 
| 2024-08-12 | Herabstufung | Raymond James | Outperform → Mkt Perform | 
| 2024-07-03 | Herabstufung | Barclays | Overweight → Equal Weight | 
| 2024-03-07 | Fortgesetzt | JP Morgan | Overweight | 
| 2023-12-20 | Eingeleitet | Raymond James | Outperform | 
| 2023-08-03 | Hochstufung | TD Cowen | Market Perform → Outperform | 
| 2023-01-31 | Fortgesetzt | Wedbush | Outperform | 
| 2022-10-21 | Fortgesetzt | Jefferies | Buy | 
| 2022-01-03 | Fortgesetzt | JP Morgan | Overweight | 
| 2021-07-26 | Hochstufung | JP Morgan | Neutral → Overweight | 
| 2021-04-21 | Fortgesetzt | JP Morgan | Neutral | 
| 2021-04-09 | Eingeleitet | Berenberg | Buy | 
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform | 
| 2021-02-11 | Herabstufung | Northland Capital | Outperform → Market Perform | 
| 2021-01-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform | 
| 2020-09-21 | Hochstufung | Northland Capital | Market Perform → Outperform | 
| 2020-07-06 | Bestätigt | Needham | Buy | 
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral | 
| 2020-04-07 | Eingeleitet | Northland Capital | Outperform | 
| 2020-03-20 | Hochstufung | SVB Leerink | Mkt Perform → Outperform | 
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy | 
| 2020-01-24 | Eingeleitet | SunTrust | Buy | 
| 2020-01-23 | Eingeleitet | SunTrust | Buy | 
| 2019-11-06 | Eingeleitet | BTIG Research | Buy | 
| 2019-06-11 | Eingeleitet | Barclays | Overweight | 
| 2019-05-06 | Hochstufung | Mizuho | Underperform → Neutral | 
| 2019-05-02 | Hochstufung | Stifel | Sell → Hold | 
| 2019-02-01 | Herabstufung | Mizuho | Neutral → Underperform | 
| 2018-08-06 | Herabstufung | BofA/Merrill | Buy → Neutral | 
| 2018-04-09 | Bestätigt | H.C. Wainwright | Buy | 
| 2018-03-21 | Bestätigt | Mizuho | Neutral | 
| 2018-02-16 | Herabstufung | Needham | Buy → Hold | 
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy | 
| 2018-01-04 | Bestätigt | Canaccord Genuity | Buy | 
| 2018-01-03 | Eingeleitet | Leerink Partners | Mkt Perform | 
                    Alle ansehen
                     
                  
                Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
Pacira BioSciences Inc. recovery potential after sell off2025 Market Overview & Community Consensus Stock Picks - newser.com
How to integrate Pacira BioSciences Inc. into portfolio analysis toolsTrade Risk Report & AI Based Buy and Sell Signals - newser.com
Real time social sentiment graph for Pacira BioSciences Inc.2025 Geopolitical Influence & Reliable Breakout Stock Forecasts - newser.com
Is Pacira BioSciences Inc. stock poised for growthBuy Signal & Free Accurate Trade Setup Notifications - newser.com
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025 - markets.businessinsider.com
Chart based analysis of Pacira BioSciences Inc. trendsJuly 2025 Breakouts & Safe Swing Trade Setups - newser.com
Pacira BioSciences Inc. stock retracement – recovery analysis2025 Growth vs Value & High Accuracy Buy Signal Tips - newser.com
Pacira Biosciences, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Trends - Markets Mojo
Pacira BioSciences (PCRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Pacira BioSciences (Nasdaq: PCRX) sets Nov. 6 third-quarter results; call at 4:30 p.m. ET - Stock Titan
Will Pacira BioSciences Inc. stock keep outperforming rivalsMarket Sentiment Report & Technical Analysis for Trade Confirmation - newser.com
Can a trend reversal in Pacira BioSciences Inc. lead to recoveryGap Down & Precise Buy Zone Tips - newser.com
Why Pacira BioSciences Inc. (82P) stock could outperform next yearCEO Change & AI Based Buy and Sell Signals - newser.com
What is the fair value estimate for Pacira BioSciences Inc. (82P) stock in 2025Market Trend Review & Weekly Momentum Stock Picks - newser.com
Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee - markets.businessinsider.com
Building trade automation scripts for Pacira BioSciences Inc.July 2025 Setups & AI Forecast Swing Trade Picks - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences, Inc. Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-To-Severe Osteoarthritis of the Knee - MarketScreener
Pacira BioSciences (PCRX) Reports Promising Three-Year Findings for PCRX-201 - GuruFocus
Is Pacira BioSciences Inc. stock a buy on dipsForecast Cut & Smart Investment Allocation Insights - Fundação Cultural do Pará
Pacira Biosciences Increceives Paragraph IV notice from Qilu Pharmaceutical - MarketScreener
Pacira BioSciences receives patent challenge for EXPAREL from Chinese firm - Investing.com
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL® - The Manila Times
Pacira BioSciences Receives PIV Notice from Qilu Pharmaceutical Regarding Generic EXPAREL Patent Claims - Quiver Quantitative
Pacira BioSciences (NASDAQ: PCRX) notes PIV ANDA for EXPAREL; 45 days to file suit - Stock Titan
How Pacira BioSciences Inc. stock trades before earnings2025 Risk Factors & Low Drawdown Momentum Ideas - newser.com
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
        In Yahoo öffnen
        |
        In Google öffnen
            |
            In Finviz öffnen
        |
        In MarketWatch öffnen
            |
            Öffnen Sie in EDGAR    
        |
        Offen in Reuters
    
    
                Kapitalisierung:
                 
                  | 
                Volumen (24h):
                 
            
         
                     
                             Holen Sie sich die Stockscreener-App
                    Holen Sie sich die Stockscreener-App